![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 7
2020
Holch, J. W.; Held, S.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Kaiser, F.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Einem, J. C. von; Michl, M. und Heinemann, V
(2020):
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
In: Annals of Oncology, Bd. 31, Nr. 1: S. 72-78
2018
Holch, J. W.; Ricard, I.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Jelas, I.; Modest, D. P.; Westphalen, C. B.; Einem, J. C. von; Michl, M. und Heinemann, V.
(2018):
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
In: European Journal of Cancer, Bd. 106: S. 115-125
2017
Modest, Dominik P.; Ricard, Ingrid; Stintzing, Sebastian; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Westphalen, C. B.; Holch, Julian W.; Einem, J. C. von; Held, S. und Heinemann, Volker
(2017):
Evaluation of survival across several treatment lines in
metastatic colorectal cancer: analysis of the FIRE-3 trial (AIO KRK0306).
In: European Journal of Cancer, Bd. 84: S. 262-269
Holch, J. W.; Stintzing, S.; Held, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Kirchner, T.; Einem, J. C. von; Modest, D. P. und Heinemann, V.
(2017):
Right-sided colorectal cancer (RC): response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR).
In: Oncology Research and Treatment, Bd. 40: S. 164-165
2016
Stahler, A.; Heinemann, V.; Clemens, G.; Crispin, A.; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2016):
Prevalence and influence on outcome of Neuregulin- (NRG1), HER2/neu- and HER3-expression in patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based first-line regimens (FUFIRI vs. mIROX) in the FIRE 1-trial.
In: Oncology Research and Treatment, Bd. 39: S. 72
2015
Stahler, A.; Heinemann, V.; Giessen-Jung, C.; Crispin, Alexander; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2015):
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
In: International Journal of Cancer, Bd. 138, Nr. 3: S. 739-746
2014
Modest, Dominik P.; Schulz, Christoph; Fischer von Weikersthal, Ludwig; Quietzsch, Detlef; Einem, J. C. von; Schalhorn, Andreas; Vehling-Kaiser, Ursula; Laubender, Rüdiger P.; Giessen, Clemens; Stintzing, Sebastian und Heinemann, Volker
(2014):
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
In: Anticancer Drugs, Bd. 25, Nr. 2: S. 212-218
[PDF, 442kB]